Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Strand

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Journal of Clinical & Laboratory Immunology|February 1, 1983
Lymphocyte subsets in Sjogren's syndrome: a quantitative analysis using monoclonal antibodies and the fluorescence-activated cell sorterA Bakhshi, N Miyasaka, P Kavathas, et al.
Lupus|July 3, 2013
Limitations of current treatments for systemic lupus erythematosus: a patient and physician surveyV Strand, C Galateanu, D S Pushparajah, et al.
The Journal of Rheumatology|May 22, 2001
A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. OMERACT Drug Safety Working PartyJ A Lipani, V Strand, K Johnson, et al.
Rheumatology (Oxford, England)|October 26, 2006
Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 yearsV Strand, A Balbir-Gurman, K Pavelka, et al.
The Journal of Rheumatology|March 15, 2001
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important DifferenceD E Beaton, C Bombardier, J N Katz, et al.
European Journal of Oral Sciences|November 20, 2018
Effect of glycerol on reconstructed human oral mucosaSiri F Kvalheim, Victoria Xenaki, Arild Kvalheim, et al.
The Journal of Rheumatology|February 1, 1995
Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugateG W Cannon, D A Marble, M M Griffiths, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Mechanism of action for leflunomide in rheumatoid arthritisR I Fox, M L Herrmann, C G Frangou, et al.
The Journal of Rheumatology|April 1, 1997
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT IIIN Bellamy, J Kirwan, M Boers, et al.
BMC Rheumatology|March 12, 2020
Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world studyA Deodhar, V Strand, P G Conaghan, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Journal of Clinical & Laboratory Immunology|February 1, 1983
Lymphocyte subsets in Sjogren's syndrome: a quantitative analysis using monoclonal antibodies and the fluorescence-activated cell sorterA Bakhshi, N Miyasaka, P Kavathas, et al.
Lupus|July 3, 2013
Limitations of current treatments for systemic lupus erythematosus: a patient and physician surveyV Strand, C Galateanu, D S Pushparajah, et al.
The Journal of Rheumatology|May 22, 2001
A proposal for developing a large patient population cohort for longterm safety monitoring in rheumatoid arthritis. OMERACT Drug Safety Working PartyJ A Lipani, V Strand, K Johnson, et al.
Rheumatology (Oxford, England)|October 26, 2006
Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 yearsV Strand, A Balbir-Gurman, K Pavelka, et al.
The Journal of Rheumatology|March 15, 2001
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important DifferenceD E Beaton, C Bombardier, J N Katz, et al.
European Journal of Oral Sciences|November 20, 2018
Effect of glycerol on reconstructed human oral mucosaSiri F Kvalheim, Victoria Xenaki, Arild Kvalheim, et al.
The Journal of Rheumatology|February 1, 1995
Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugateG W Cannon, D A Marble, M M Griffiths, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Mechanism of action for leflunomide in rheumatoid arthritisR I Fox, M L Herrmann, C G Frangou, et al.
The Journal of Rheumatology|April 1, 1997
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT IIIN Bellamy, J Kirwan, M Boers, et al.
BMC Rheumatology|March 12, 2020
Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world studyA Deodhar, V Strand, P G Conaghan, et al.
Pageof 15